Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ⁹-THC in Cannabis Users

Oral Δ9-tetrahydrocannabinol (Δ9-THC) has been evaluated as a medication for cannabis dependence, but repeated administration of acute oral doses up to 40 mg has not been effective at reducing drug-taking behavior. Larger doses might be necessary to affect cannabis use. The purpose of the present study was therefore to determine the physiological and behavioural effects of oral Δ9-THC at acute doses higher than those tested previously. The...